Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2 Negative Breast Carcinoma”

550 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 550 results

Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Not applicableUnknownNCT06348654
What this trial is testing

New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer

Who this might be right for
Breast CancerNarrative MedicineHER2-negative Breast Cancer+1 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 50
Early research (Phase 1)Looking for participantsNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Testing effectiveness (Phase 2)Looking for participantsNCT06042894
What this trial is testing

SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 58
Testing effectiveness (Phase 2)Ended earlyNCT01498588
What this trial is testing

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerBreast Tumors+3 more
Emory University 7
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Testing effectiveness (Phase 2)Looking for participantsNCT06642545
What this trial is testing

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Testing effectiveness (Phase 2)Looking for participantsNCT06837792
What this trial is testing

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Who this might be right for
Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Yonsei University 141
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05986071
What this trial is testing

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 57
Testing effectiveness (Phase 2)Ended earlyNCT01980277
What this trial is testing

Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 68
Large-scale testing (Phase 3)Looking for participantsNCT05430399
What this trial is testing

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsLocally Advanced or Metastatic Breast Cancer
Sun Yat-sen University 349
Testing effectiveness (Phase 2)UnknownNCT05560334
What this trial is testing

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Early research (Phase 1)Study completedNCT02027376
What this trial is testing

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 12
Not applicableLooking for participantsNCT06261918
What this trial is testing

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Who this might be right for
Breast CancerMetabolic Syndrome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120
Large-scale testing (Phase 3)Study completedNCT02163694
What this trial is testing

Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 513
Load More Results